NCT05020444: Phase 1 - TriPRIL CAR T Cells in Multiple Myeloma
Updated: Feb 10
NCT05020444: Phase 1 - TriPRIL CAR T Cells in Multiple Myeloma
This research study involves the study of TriPRIL CAR T Cells for treating people with relapsed or refractory multiple myeloma and to understand the side effects when treated with TriPRIL CAR T Cells.
This research study involves the study drugs:.
TriPRIL CAR T Cells
Fludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process
Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT05020444
Official Title: A Phase I Clinical Trial With TriPRIL CAR T Cells for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
First Posted: August 25, 2021
Click here for details on ClinicalTrials.gov
Drug: TriPRIL CAR T Cells
Drug: Cyclophosphamide
Drug: Fludarabine
Autologous BCMA/TACI-targeted Trimeric APRIL-based CAR T Cells (Code C183542)
Autologous Anti-BCMA/Anti-TACI Trimeric APRIL-based CAR T-cells
Autologous Anti-BCMA/TACI Trimeric APRIL-based CAR-T Cells
Autologous BCMA/TACI-targeted Trimeric APRIL-based CAR T Cells
TriPRIL CAR T Cells
Location
United States, Massachusetts